Cabozantinib for Pancreatic Neuroendocrine Tumors

Not currently recruiting at 507 trial locations

Overseen By Jonathan R. Strosberg

Age: 18+

Sex: Any

Trial Phase: Phase 3

Sponsor: National Cancer Institute (NCI)

Must not be taking: Warfarin, Strong CYP3A4 inhibitors

Disqualifiers: Congestive heart failure, Cardiac arrhythmia, Hypertension, others

Pivotal Trial (Near Approval) This treatment is in the last trial phase before FDA approval

Prior Safety Data This treatment has passed at least one previous human trial

Breakthrough Therapy This drug has been fast-tracked for approval by the FDA given its high promise

Approved in 2 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: 13

Duration: 36 months

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores the effectiveness of cabozantinib, a chemotherapy drug, compared to a placebo in treating neuroendocrine or carcinoid tumors that have spread. Cabozantinib works by blocking certain receptors to slow tumor growth. It suits patients with diagnosed neuroendocrine tumors that have spread and progressed after other treatments. Participants will receive either cabozantinib or a placebo, with their condition monitored through scans and tests. As a Phase 3 trial, this study represents the final step before FDA approval, offering patients a chance to contribute to potentially groundbreaking treatment advancements.

Will I have to stop taking my current medications?

The trial requires stopping certain medications before participating. You must stop taking strong CYP3A4 inhibitors and inducers at least 14 days before joining. Full-dose oral anticoagulants are not allowed, but low-dose aspirin and stable doses of low molecular weight heparin are permitted.

Is there any evidence suggesting that cabozantinib S-malate is likely to be safe for humans?

Research shows that cabozantinib, a drug targeting specific cancer growth signals, has been safely used in patients with pancreatic neuroendocrine tumors. The FDA has approved cabozantinib for certain tumors, including these, indicating it has undergone safety testing in humans.

Some patients taking cabozantinib have experienced side effects such as tiredness, diarrhea, and loss of appetite, which can vary among individuals. Overall, patients in past studies generally tolerated the drug well.

Prospective trial participants should discuss potential side effects with a healthcare provider, who can offer personalized information based on individual health needs. ^{1 2 3 4 5}

Why do researchers think this study treatment might be promising?

Cabozantinib S-malate is unique because it targets multiple pathways involved in tumor growth and spread, particularly the MET and VEGFR2 pathways, which are not the primary focus of most standard treatments for pancreatic neuroendocrine tumors. While current options like everolimus and sunitinib primarily target other pathways, cabozantinib offers a novel approach by potentially inhibiting tumor angiogenesis and metastasis more effectively. Researchers are excited about its potential to improve outcomes for patients with this rare and challenging cancer type, offering hope for a more effective treatment option.

What evidence suggests that cabozantinib might be an effective treatment for pancreatic neuroendocrine tumors?

Research has shown that cabozantinib may effectively treat pancreatic neuroendocrine tumors (pNET). In this trial, one group of participants will receive cabozantinib, while another group will receive a placebo. One study found that patients taking cabozantinib lived for an average of 13.8 months without their cancer worsening, which was longer than those on a placebo. Another study found that cabozantinib reduced the risk of cancer progression or death by 77% compared to a placebo. These findings suggest that cabozantinib could be a strong option for slowing tumor growth and extending the time patients live without disease progression. ^{1 2 4 6 7}

Who Is on the Research Team?

Jennifer A Chan

Principal Investigator

Alliance for Clinical Trials in Oncology

Are You a Good Fit for This Trial?

Adults with advanced neuroendocrine or carcinoid tumors that have spread and worsened after prior therapy can join. They must be able to swallow pills, not pregnant, no severe allergies to similar drugs as cabozantinib/placebo, and have a decent performance status (able to carry out daily activities). People with certain heart conditions, uncontrolled blood pressure, recent bleeding or clotting events, or other cancers within the last 5 years cannot participate.

Inclusion Criteria

Not pregnant and not nursing

You do not have any hollow spaces in your lungs.

I do not have a history of inherited long QT syndrome.

Exclusion Criteria

Patient is living outside the US

My cancer is not a high-grade neuroendocrine, adenocarcinoid, or goblet cell carcinoid tumor.

I have had a condition where my lymphocytes grow abnormally.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

1 visit (in-person)

Treatment

Participants receive cabozantinib S-malate or placebo orally once daily in 28-day cycles, with regular blood and urine sample collection, and imaging studies

36 months

Monthly visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment completion, with follow-up every 12 weeks until disease progression or new therapy, then every 6 months

Up to 8 years

Every 12 weeks, then every 6 months (in-person)

What Are the Treatments Tested in This Trial?

Interventions

• Cabozantinib S-malate

Trial Overview

This phase III trial is testing if cabozantinib works better than a placebo for treating advanced neuroendocrine or carcinoid tumors. Cabozantinib is a chemotherapy drug that blocks specific receptors which may slow tumor growth. Patients will also undergo scans and quality-of-life assessments.

How Is the Trial Designed?

Group I: Arm I (cabozantinib S-malate) Experimental Treatment 6 Interventions

Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study.

Group II: Arm II (placebo) Placebo Group 6 Interventions

Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo blood and urine sample collection, and CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.

Cabozantinib S-malate is already approved in United States, European Union for the following indications:

Approved in United States as Cabometyx for:

• Advanced renal cell carcinoma (RCC)
• Hepatocellular carcinoma (HCC)
• Locally advanced or metastatic differentiated thyroid cancer (DTC)

Approved in United States as Cometriq for:

• Medullary thyroid cancer

Approved in European Union as Cabometyx for:

• Advanced renal cell carcinoma (RCC)
• Hepatocellular carcinoma (HCC)
• Locally advanced or metastatic differentiated thyroid cancer (DTC)

Who Is Running the Clinical Trial?

National Cancer Institute (NCI)

Lead Sponsor

Trials

14,080

Recruited

41,180,000+

Published Research Related to This Trial

Cabozantinib is an effective treatment for advanced hepatocellular carcinoma (HCC) after failure of sorafenib, showing significant improvement in overall survival and progression-free survival compared to placebo in the phase 3 CELESTIAL trial.

Common side effects of cabozantinib include palmar-plantar erythrodysesthesia, hypertension, fatigue, and diarrhea, which are important to manage in patients undergoing treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cabozantinib for the Treatment of Advanced Hepatocellular Carcinoma: Current Data and Future Perspectives. Trojan, J.[2021]

Surufatinib, a tyrosine kinase inhibitor, is well-absorbed in both rats and humans, with a median time to peak concentration of 4 hours after oral dosing, and a significantly longer half-life in humans (23.3 hours) compared to rats (3.12-6.48 hours).

The primary route of elimination for surufatinib in both species is fecal excretion, accounting for about 87% of the dose, indicating that the drug is largely eliminated unchanged, with no single metabolite making up more than 10% of the total radioactivity in circulation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans. Li, K., Ma, S., Miao, L., et al.[2021]

The LOLA trial is the first prospective phase II study evaluating the safety and efficacy of cabozantinib combined with lanreotide in patients with advanced well-differentiated neuroendocrine tumors (NETs), aiming to enroll up to 69 participants over 42 months.

Cabozantinib targets key pathways in NET pathogenesis, and the trial will assess its optimal dosing and safety profile, with a focus on overall response rate and potential biomarkers, which could provide valuable insights for treating these rare tumors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Assessing the safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic and thoracic neuroendocrine tumors: rationale and protocol of the phase II LOLA trial. Corti, F., Brizzi, MP., Amoroso, V., et al.[2023]

Cabozantinib (CAB) demonstrated significant antitumor activity against neuroendocrine tumors (NETs) in both in vitro cell cultures and in vivo models, showing a dose-dependent effect on cell viability and proliferation.

CAB not only inhibited cell growth but also halted cell cycle progression and significantly reduced NET-induced angiogenesis and cell migration in a zebrafish model, suggesting its potential as an effective treatment for NETs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cabozantinib in neuroendocrine tumors: tackling drug activity and resistance mechanisms. Cella, CA., Cazzoli, R., Fazio, N., et al.[2023]

Cabozantinib is an oral multitargeted tyrosine kinase inhibitor approved for advanced renal cell carcinoma and progressive metastatic medullary thyroid cancer, showing potential advantages over single-receptor TKIs.

The article reviews clinical trial data and management strategies for common adverse events associated with cabozantinib, highlighting its expanding use in treating various cancers such as prostate, hepatocellular, and lung cancer.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. Markowitz, JN., Fancher, KM.[2019]

In a study of 76 patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs), the combination of 177Lu-DOTATATE and capecitabine showed a significantly higher objective response rate (38%) and longer progression-free survival (54 months) compared to octreotide LAR, which had a 15% response rate and 16 months of progression-free survival.

Both treatment regimens had similar rates of severe side effects (grade 3 or 4 toxicities), indicating that while 177Lu-DOTATATE plus capecitabine is more effective, it does not appear to increase the risk of serious adverse events compared to octreotide LAR.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A Single-Institution Experience. Satapathy, S., Mittal, BR., Sood, A., et al.[2021]

In a phase II study involving 109 patients with advanced neuroendocrine tumors, sunitinib demonstrated a 16.7% objective response rate in pancreatic endocrine tumor patients and 2.4% in carcinoid patients, with a significant proportion of patients experiencing stable disease.

The treatment resulted in a median time to tumor progression of 7.7 months for pancreatic neuroendocrine tumors and 10.2 months for carcinoid tumors, with one-year survival rates of approximately 81% for pancreatic and 83% for carcinoid patients, indicating potential efficacy and safety for further investigation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Activity of sunitinib in patients with advanced neuroendocrine tumors. Kulke, MH., Lenz, HJ., Meropol, NJ., et al.[2022]

In a study of 67 patients with pancreatic and small bowel neuroendocrine tumors, treatment with (90)Y-DOTATATE resulted in a median progression-free survival of 25 months for pancreatic NETs and 28 months for small bowel NETs, indicating its effectiveness in managing these tumors.

The median overall survival was 42 months for pancreatic NETs and 38.5 months for small bowel NETs, with no significant differences in survival outcomes based on tumor type, suggesting that (90)Y-DOTATATE may be equally effective for both types of NETs.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms. Rogowski, W., Wachuła, E., Lewczuk, A., et al.[2017]

Citations

1.

cabometyxhcp.com

cabometyxhcp.com/net-treatment/cabinet-data/pnet-efficacy

Previously treated pNET efficacy data

CABOMETYX quadrupled median PFS in pNET 1. 78% reduction in risk of progression or death. PFS results in pNET patients across select disease characteristics.

2.

pmc.ncbi.nlm.nih.gov

pmc.ncbi.nlm.nih.gov/articles/PMC11821447/

Phase 3 Trial of Cabozantinib in Advanced Neuroendocrine ...

In patients with extra-pancreatic NET, median progression-free survival with cabozantinib was 8.4 months compared to 3.9 months with placebo ( ...

3.

nejm.org

nejm.org/doi/full/10.1056/NEJMoa2403991?outputType=chromeless

Phase 3 Trial of Cabozantinib to Treat Advanced ...

In the cohort of 95 patients with pancreatic neuroendocrine tumors, the median progression-free survival with cabozantinib was 13.8 months, as ...

4.

ir.exelixis.com

ir.exelixis.com/news-releases/news-release-details/exelixis-announces-results-subgroup-analysis-cabinet-phase-3

Press Release - Exelixis

CABOMETYX reduced the risk of disease progression or death by 81% versus placebo in patients with advanced lung or thymic neuroendocrine ...

5.

ipsen.com

ipsen.com/press-releases/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-in-advanced-neuroendocrine-tumors-2946663/

Final results from CABINET Phase III trial reinforce efficacy ...

These data demonstrated a statistically significant reduction in the risk of disease progression or death for Cabometyx versus placebo of 77% ( ...

6.

fda.gov

fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabozantinib-adults-and-pediatric-patients-12-years-age-and-older-pnet-and-epnet

FDA approves cabozantinib for pNET and epNET

OS data were not mature with 83 (63% of patients enrolled) deaths in the cabozantinib arm and 40 (60% of patients enrolled) in the placebo arm ( ...

7.

onclive.com

onclive.com/view/cabozantinib-wins-eu-approval-for-previously-treated-advanced-pancreatic-and-extra-pancreatic-neuroendocrine-tumors

Cabozantinib Wins EU Approval for Previously Treated ...

The European Commission has approved cabozantinib for the treatment of patients with pancreatic and extrapancreatic neuroendocrine tumors.